Stockreport

Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells

Phio Pharmaceuticals Corp.  (PHIO) 
Last phio pharmaceuticals corp. earnings: 11/12 07:45 am Check Earnings Report
PDF -Injection in murine tumors shows the compound is well tolerated -Studies support ongoing clinical trial of PH-762 as a neoadjuvant therapy for treatment of cSCC, melan [Read more]